
Biphasic Insulin Aspart
NOVOMIX

NOVOMIX
Novomix 30 Flexpen Inj 100IU/mL 5S
- SKU:
- 009126
- Generic Name:
- Biphasic Insulin Aspart
Novomix 30 Flexpen Inj 100IU/mL 5S
IMPORTANT NOTICE:
For this product, a doctor's prescription is required. Please do not forget to attach a copy of your valid prescription(.jpeg, bmp, gif, jpg, jpeg, jpe, jif, jfif, jfi, png, wbmp, xbm, tiff format). After you have placed your order, our pharmacist will be in touch to confirm your order and validate your prescription. Please present the original copy of your prescription upon the arrival of your order.
An item like loose capsule/tablets, ampules, vials, and refrigerated items is not subject for merchandise return or exchange upon completing the purchase.
PRODUCT DETAILS | |
Brand Name | NovoMix® 30 FlexPen® |
Generic Name | Insulin aspart |
Strength | 1 ml of the suspension contains 100 U of soluble insulin aspart*/protamine-crystallised insulin aspart* in the ratio 30/70 (equivalent to 3.5 mg). |
Dosage Form | Suspension for injection in pre-filled pen |
Indication/Usage | Treatment of patients with diabetes mellitus requiring insulin. |
Dosage and Administration | Dosing is individual and determined in accordance with the needs of the patient. In patients with type 2 diabetes, NovoMix® 30 can be given as monotherapy. NovoMix® 30 can also be given in combination with oral antidiabetic drugs if the patient's blood glucose is inadequately controlled with oral antidiabetic drugs alone. Insulin naïve patients: For patients with type 2 diabetes, the recommended starting dose of NovoMix® 30 is 6 U at breakfast and 6 U at dinner (evening meal). However, it can also be initiated once daily with 12 U at dinner (evening meal). When transferring a patient from biphasic human insulin to NovoMix® 30, start with the same dose and regimen. Then titrate according to individual needs. Special Populations (with glucose monitoring): Can be used in the elderly however there is limited experience with the use of NovoMix® 30 in combination with OADs in patients older than 75 years. Renal or hepatic impairment may reduce the patient’s insulin requirements. Can be used in children and adolescents aged 10 years and above when premixed insulin is preferred. Limited clinical data exist for children aged 6 to 9 years. For subcutaneous use only. |
Warning and Precautions | Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal. Hypoglycaemia may result from omission of a meal or unplanned strenuous physical exercise, and may occur if the insulin dose is too high in relation to the insulin requirement. Transferring a patient to another type, brand or manufacturer of insulin must be done under medical supervision and may result in the need for a change in dosage. As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Cases of congestive heart failure have been reported when thiazolidinediones were used in combination with insulin, especially in patients with risk factors for development of congestive heart failure. Thiazolidinediones should be discontinued if any deterioration in cardiac symptoms occurs. Avoid accidental mix-ups between NovoMix® and other insulin products. Formation of insulin antibodies upon administration of insulin. |
Contraindication | Hypersensitivity to the active substances or to any of the excipients. |
Requires prescription? | Yes |
Storage Conditions | When not in use: Store in a refrigerator (2°C – 8°C). Do not freeze. After first opening or carried as a spare: The product may be stored for a maximum of 4 weeks. Do not store above 30°C. Can be stored in a refrigerator (2°C – 8°C). |
Manufacturer | Novo Nordisk A/S |
Regulatory Classification | Prescription |